What is the 13F Pro Quality Score for PHGE?

13F Pro ranks BiomX Inc. (PHGE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PHGE's current score at https://13fpro.ai/company/PHGE (free sign-up required for the full ranking).

Where does 13F Pro source PHGE data?

All BiomX Inc. fundamentals and ownership data come directly from SEC EDGAR. BiomX Inc. files with the SEC under CIK 1739174. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PHGE in?

BiomX Inc. (PHGE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PHGE research updated on 13F Pro?

PHGE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BiomX Inc.(PHGE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1739174 PHGE stock profile & AI dashboard →

13F Pro Quality Score

29.4/100

Rank #2,468 of 2,884 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

0.6/100

Earnings Quality

36.0/100

Free Cash Flow

30.0/100

Institutional Flow

64.4/100

Revenue Scale

30.0/100

Dilution Risk

30.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PHGE Scores 29/100

exact factor attribution · 2026-08-18

PHGE's composite is held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.7 pts

64th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.0 pts

30th pct

Earnings quality

-1.4 pts

36th pct

Free cash flow

-3.0 pts

30th pct

Profitability

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PHGE Stock Analysis & AI Quality Score

Data updated 2026-08-18

AI stock analysis and institutional research for BiomX Inc. (PHGE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHGE at 29.4/100 on a 32-signal composite quality model, placing it at rank #2,468 of 2,884 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.6) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BiomX Inc. reports quarterly revenue of $332.0K, net income of $-3.8M. Top institutional holders of PHGE by reported 13-F value include Nantahala Capital Management, COMMONWEALTH EQUITY SERVICES, Ikarian Capital, based on the most recent SEC filings. PHGE trades on the NYSE exchange and files with the SEC under CIK 1739174. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BiomX Inc. directly from SEC EDGAR.

✦

Fun facts about BiomX Inc.

Quirks, history, and lore behind PHGE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on NYSE American · focused on developing targeted therapies for diseases driven by the microbiome.
2
The Numbers
A micro-cap with minimal revenue and a cash-burn model typical of early-stage biotech — its fate rides entirely on pipeline milestones, not sales.
3
The History
Founded around 2015 and backed by research partnerships, it was built on the premise that bacteriophages — viruses that kill bacteria — could become precision medicines.
4
The Secret
Its core platform engineers phage cocktails designed to target specific harmful bacteria while leaving the rest of the gut microbiome untouched — basically a sniper rifle against bugs that antibiotics miss.
5
The Lore
Its pipeline has included programs targeting colorectal cancer and inflammatory skin conditions, betting that the ancient viral enemies of bacteria are medicine's next frontier.
6
The Giveaway
The ticker is literally PHGE — short for phage — and the company name fuses "biome" with an X, because every biotech needs an X.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$332.0K

Net Income

Q2 2026

$-3.8M

D/E Ratio

Q2 2026

0.04

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-104.2% YoY

$-36.2MFY 2025

FY22 $-28.3MFY23 $-26.2MFY24 $-17.7MFY25 $-36.2M

Operating Income

+6.9% YoY

$-41.5MFY 2025

FY22 $-27.2MFY23 $-25.3MFY24 $-44.5MFY25 $-41.5M

EPS (Diluted)

-61.9% YoY

$22.19FY 2025

FY22 $0.95FY23 $5.10FY24 $58.31FY25 $22.19

Total Assets

-86.6% YoY

$5.8MFY 2025

FY22 $45.5MFY23 $25.0MFY24 $43.2MFY25 $5.8M

Total Debt

—FY 2025

FY22 $20.0MFY23 $17.0MFY24 —FY25 —

Op. Cash Flow

+28.6% YoY

$-26.4MFY 2025

FY22 $-29.1MFY23 $-21.3MFY24 $-37.0MFY25 $-26.4M

Free Cash Flow

+28.7% YoY

$-26.4MFY 2025

FY22 $-29.2MFY23 $-21.3MFY24 $-37.0MFY25 $-26.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-36.2M -104.2%	$-17.7M +32.3%	$-26.2M +7.6%	$-28.3M +21.8%	$-36.2M -20.4%	$-30.1M
Operating Income	$-41.5M +6.9%	$-44.5M -75.6%	$-25.3M +6.9%	$-27.2M +23.2%	$-35.5M -17.2%	$-30.3M
EPS (Diluted)	$22.19 -61.9%	$58.31 +1043.3%	$5.10 +436.8%	$0.95 -31.7%	$1.39	—
Total Assets	$5.8M -86.6%	$43.2M +72.7%	$25.0M -45.0%	$45.5M -41.6%	$78.0M +10.8%	$70.4M
Total Debt	—	—	$17.0M -15.0%	$20.0M +26.2%	$15.8M +168.3%	$5.9M
Operating Cash Flow	$-26.4M +28.6%	$-37.0M -73.7%	$-21.3M +26.8%	$-29.1M -5.5%	$-27.6M -12.8%	$-24.4M
Free Cash Flow	$-26.4M +28.7%	$-37.0M -73.5%	$-21.3M +26.9%	$-29.2M +6.6%	$-31.3M -22.8%	$-25.5M

Get alerted when PHGE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BiomX Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PHGE

Nantahala Capital Management, LLC
$215.2K634,995 sh
COMMONWEALTH EQUITY SERVICES, LLC
$8.1K23,414 sh
Ikarian Capital, LLC
$6.8K19,473 sh
Kovack Advisors, Inc.
$6.0K17,200 sh
JPMORGAN CHASE & CO
$552.001,538 sh
BARCLAYS PLC
$458.001,316 sh
SBI Securities Co., Ltd.
$176.00505 sh
Caitong International Asset Management Co., Ltd
$0.001 sh
DANSKE BANK A/S
$0.001 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$215.2K	634,995
COMMONWEALTH EQUITY SERVICES, LLC	$8.1K	23,414
Ikarian Capital, LLC	$6.8K	19,473
Kovack Advisors, Inc.	$6.0K	17,200
JPMORGAN CHASE & CO	$552.00	1,538
BARCLAYS PLC	$458.00	1,316
SBI Securities Co., Ltd.	$176.00	505
Caitong International Asset Management Co., Ltd	$0.00	1
DANSKE BANK A/S	$0.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PHGE on your watchlist

Track score changes the day BiomX Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PHGE a good stock to buy?

13F Pro's AI-powered analysis of BiomX Inc. (PHGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PHGE are available on the PHGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PHGE is classified as a small company.

Which hedge funds own PHGE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PHGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BiomX Inc.'s investment landscape.